ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer mulls sale of consumer business

by Lisa M. Jarvis
October 16, 2017 | APPEARED IN VOLUME 95, ISSUE 41

Pfizer is considering selling or spinning off its consumer health care division, one of the world’s biggest makers of over-the-counter drugs. Stock analysts expect the unit, which had sales last year of $3.4 billion, to fetch up to $15 billion. Industry watchers say the potential move comes as Pfizer considers a sizable acquisition to bolster its research-driven drug arm. Merck KGaA put its consumer products business up for sale last month.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment